SUN PHARMACEUTICAL INDUSTRIES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,515 INR | -1.63% |
|
-1.47% | +20.29% |
| Sales 2024 * | 485B 5.83B | Sales 2025 * | 538B 6.46B | Capitalization | 3,695B 44.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 93.03B 1.12B | Net income 2025 * | 113B 1.35B | EV / Sales 2024 * | 7.41 x |
| Net cash position 2024 * | 101B 1.21B | Net cash position 2025 * | 167B 2.01B | EV / Sales 2025 * | 6.56 x |
| P/E ratio 2024 * |
39.4
x | P/E ratio 2025 * |
32.8
x | Employees | 41,000 |
| Yield 2024 * |
0.79% | Yield 2025 * |
0.92% | Free-Float | 45.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sun Pharmaceutical Industries Ltd.
More recommendations
More press releases
More news
| 1 day | -1.63% | ||
| 1 week | -1.47% | ||
| Current month | -6.51% | ||
| 1 month | -5.20% | ||
| 3 months | +9.92% | ||
| 6 months | +34.97% | ||
| Current year | +20.29% |
1 week
1 503.70
1 562.45
1 month
1 503.701 638.85
Current year
1 257.151 638.85
1 year
922.451 638.85
3 years
631.001 638.85
5 years
312.001 638.85
10 years
312.001 638.85
| Managers | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Founder | 68 | 81-12-31 | |
| Director of Finance/CFO | - | 17-06-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 68 | 81-12-31 | |
Rama Bijapurkar
BRD | Director/Board Member | 67 | 21-05-20 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 23-06-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.72% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1,515 | -1.63% | 853 369 |
| 24-04-22 | 1,540 | +1.14% | 1,680,307 |
| 24-04-19 | 1,523 | +0.42% | 2,536,516 |
| 24-04-18 | 1,516 | -1.38% | 3,266,796 |
| 24-04-16 | 1,538 | -0.16% | 2,058,697 |
Delayed Quote NSE India S.E., April 23, 2024 at 01:50 am EDT
More quotes
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Sector
Pharmaceuticals
Calendar
2024-05-23
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
36
Last Close Price
1,540
INR
Average target price
1,570
INR
Spread / Average Target
+1.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.29% | 44.31B | |
| +20.08% | 22.17B | |
| +14.63% | 14.62B | |
| +9.20% | 13.12B | |
| +37.47% | 11.58B | |
| -8.80% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B | |
| -1.14% | 4.27B |
- Stock Market
- Equities
- SUNPHARMA Stock
